Baiyunshan Subsidiary's Norepinephrine Bitartrate Injection Passes Consistency Evaluation

Regulation
โดย Jiemian·CN·Read original
Summary · why it matters

Baiyunshan's wholly-owned subsidiary Mingxing Pharmaceutical has passed the generic drug quality and efficacy consistency evaluation for its norepinephrine bitartrate injection. The drug, with a specification of 1ml:2mg, was approved for marketing in 1982 and is used for blood pressure control in certain acute hypotensive states. Mingxing Pharmaceutical submitted its consistency evaluation application on April 16, 2025, and it was accepted on April 30. According to Menet data, domestic sales of this drug in 2025 were approximately 769 million yuan, with major manufacturers including Grand Pharmaceutical, Hefei Yifan Biotech, and Tianjin Jinyao Pharmaceutical. Mingxing Pharmaceutical's R&D investment for this consistency evaluation was approximately 1.2557 million yuan.

Impact on stocks 3

Aging Population▼ · 1 stocks
Others± Mixed · 2 stocks

Off-coverage companies 2

明兴药业Private▲ Positive
Technologyrelevance

Subsidiary's drug passes consistency evaluation, enhancing product quality and market competitiveness.

津药和平（天津）制药有限公司 (Jinyao Heping Pharmaceutical)Private▼ Negative
Competitionrelevance

Mentioned as a major manufacturer, facing increased competition from Baiyunshan's approval.

© 2026 MarketDXNews